Product Description
Mechanisms of Action: MMP Inhibitor,Collagen Inhibitor,Angiogenesis Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral,Topical
FDA Designation: *
Approval Status: Not Approved
Approved Countries: Austria | European Medicines Agency | India | Norway | Poland | United Arab Emirates
Approved Indications: None
Known Adverse Events: None
Company: Processa Pharmaceuticals
Company Location: HANOVER MD 21076
Company CEO: David Young
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Sarcoma, Kaposi|Muscular Dystrophy, Duchenne|Pneumonia|COVID-19
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| EORTC-16007 | P1 |
Completed |
Oncology Solid Tumor Unspecified |
2004-02-01 |
2019-03-21 |
Treatments |
|
| PJS-539 | P2 |
Completed |
COVID-19|Pneumonia |
2022-02-03 |
2022-04-13 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
|
| HALO-DMD-03 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2016-12-30 |
2019-03-20 |
Primary Completion Date|Study Completion Date|Treatments |
|
| HALO-DMD-02 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2016-04-30 |
2020-09-09 |
Primary Endpoints|Treatments |
|
| HALO-DMD-01 | P2 |
Terminated |
Muscular Dystrophy, Duchenne |
2016-03-30 |
2020-09-09 |
Primary Endpoints |
|
| NCI-2012-02925 | P2 |
Completed |
Sarcoma, Kaposi |
2006-12-01 |
2019-03-21 |
Treatments |